

Green Pharma Summit Roundtable output

July 20-21 2009

Opportunities, Challenges and Actions

- Most challenges are also opportunities
- Most actions would be more effective at an industry-wide level rather than an individual company level
- 7 challenges/opportunities identified based on the first day's discussions

Opportunities, Challenges and Actions

- Green products/Green labeling
 - The Pharma industry should design a system for comparing or rating the greenness of pharma products for the consumer/ customer (or someone else will do it for us and we may not like the results).
 - System should be international
 - System must rate products on a range of issues so consumers can compare apples with apples as far as possible and know when comparing apples to oranges
 - Need to allow for/make clear highly different chemistries and efficacies of different drugs even if treat similar conditions
- Waste product take back – in the US the regulatory requirements governing take back of drugs varies tremendously state to state which prevents establishment of a nationwide take back scheme.
 - DEA and hazardous waste laws inhibit and prohibit drug manufacturers establishing take back schemes.

Opportunities, Challenges and Actions

- Supply chain management
 - Opportunity to share cost and effort and combine resources for evaluating suppliers. Develop rating system for suppliers, share in auditing costs/efforts and results
 - Challenges
 - Antitrust and competitive marketing issues
 - Same suppliers manufacture different products for different companies using different process so audit criteria differ
 - For smaller pharmas effecting change at bigger suppliers can be challenging
 - May work better for indirect suppliers (not the APIs or incipient manufacturers)
 - Industry struggling with this for several years and no consensus yet – BSR's PSCI, Rx360 (consortia for auditing quality in supply chain -<http://www.rx-360.org/>) and European Chemical Industry Council's API Committee Audit Program - a standardized "Third Party Auditing" model for auditing GMP compliance of API manufacturers suppliers (http://www.api-compliance.org/apicomp_aboutus.html)

Opportunities, Challenges and Actions

- PiE- opportunity to influence the developments in this field
 - Pharma should get in front of the developments and proactively address public/regulator concerns
 - Proactively communicate and engage with public, NGOs and regulators and put PIE issues in perspective – put possibilities for harm to human health and environment in context with other issues and industries
 - Proactively establish PNECs
 - Be seen to be doing something to protect quality of tap water
 - PhRMA's PiE task force doing some of this already – need to do more.
 - Generic manufacturers are responsible for ~60% of drugs on market but not in public or regulator's cross-hairs on this and big trust issue between Pharma and generic companies – how to play nicely together?
- Lack of green chemistry being taught in academic institutes
 - Opportunity for Pharma to influence this, partner with universities, provide continuing education on green chemistry for chemists
 - Could partner with EPA on educational initiatives for greening chemists

Opportunities, Challenges and Actions

- Patients generally don't really care if our pharmaceutical products are green (they care if the drugs are going to help them), other stake holders are asking about this (shareholders, NGOs etc). So how much is it worth us really investing in this? What is the business case?
- Need a place consumers and the public can go where they can get trusted, reliable information on pharmaceuticals, their effectiveness, greenness, environmental effects etc. When people are scared they need somewhere they can turn to for trusted advice
 - Opportunity to partner with NGOs and consumer groups e.g. Healthcare without Harm / Practice Green Health